Announcement: Aurelia Bioscience has been acquired by Charnwood Molecular.

After graduating with an MChem from UMIST (now the University of Manchester) in 2001, James began his career as a bench chemist within the Discovery Research Division at GlaxoSmithKline. He made several important contributions in declaring tractable lead series for high-profile kinase targets.


James has a PhD from the University of Cambridge in main-group organometallic chemistry applied to organic synthesis, which kindled his interest in understanding chemical reactions intimately and using this knowledge to engineer optimal outcomes in complex synthetic routes.


After 13 years laboratory experience, and before joining Charnwood Molecular in 2020, James served as Technical Director and a Board member at ProSynth Ltd, with overall responsibility for quoting, project management and delivery of custom synthesis projects ranging from mg to kg scales.